Pellerano & Herrera advised ICU Medical on the Dominican Republic aspects of its $1 billion global acquisition of Hospira from Pfizer.
ICU Medical, Inc. is headquartered in California and company develops, manufactures, and sells medical technologies used in vascular therapy, oncology, and critical care applications.
Hospira Infusion Systems is a provider of injectable drugs and infusion technologies and a worldwide leader in biosimilars. Hospira was acquired by Pfizer in 2015 for approximately $17 billion.
Under the current deal, Pfizer secured $600 million in cash from ICU Medical, as well as $400 million in shares from its common stock. Pfizer now owns around 16.6% stake in ICU Medical.
Partners Luis R Pellerano and Mariangela Pellerano led the team at Pellerano & Herrera which advised ICU Medical under Dominican Republic law.
Pfizer instructed Skadden, Arps, Slate, Meagher & Flom and Ropes & Gray for the global deal. The latter firm had advised Pfizer on its 2015 acquisition of Hospira.
ICU Medical retained Latham & Watkins and Baker McKenzie.